Mesoblast Ltd. lost more than a third of its market value Tuesday (NASDAQ:MESO) as Teva Pharmaceutical Industries Ltd. returned full development and commercialization rights to its advanced chronic heart failure therapy, MPC-150-IM. Mesoblast CEO Silviu Itescu sought to cast the return as "a major win" for the company, simultaneously announcing a equity financing facility that will fund the program through completion.